Department of Ophthalmology and Visual Science,College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Ophthalmology and Visual Science, St. Vincent's Hospital, Jungbu-daero 93, Paldal-gu, Suwon, 16247, Korea.
Sci Rep. 2022 Aug 18;12(1):14103. doi: 10.1038/s41598-022-18414-2.
We compared the aqueous profiles, baseline characteristics, and clinical outcomes of 54 eyes with macular edema secondary to major branch retinal vein occlusion (BRVO) and macular BRVO. We also identified the characteristics of poor responders to anti-vascular endothelial growth factor (VEGF) injections. Aqueous inflammatory cytokine and VEGF concentrations were significantly higher in major BRVO. In optical coherence tomography, major BRVO had a higher proportion with subretinal fluid, disorganization of retinal inner layers, and ellipsoid zone disruption. Comparing the clinical outcomes, major BRVO required more intravitreal anti-VEGF injections and had a poorer visual prognosis in the first 12 months. A significantly higher proportion of patients with major BRVO required additional treatments after 6 months compared to macular BRVO. Patients who responded poorly to anti-VEGF had higher aqueous VEGF levels and central subfield thickness (CST) at baseline. In conclusion, major BRVO patients required more and longer treatments, and had worse visual prognoses. BRVO that responds poorly to anti-VEGF had greater CST and higher aqueous VEGF levels at baseline.
我们比较了 54 只因主要分支视网膜静脉阻塞(BRVO)和黄斑 BRVO 引起的黄斑水肿的眼的房水特征、基线特征和临床结果。我们还确定了对血管内皮生长因子(VEGF)抑制剂治疗反应不佳的特征。主要 BRVO 的房水炎症细胞因子和 VEGF 浓度明显更高。在光学相干断层扫描中,主要 BRVO 中有更高比例的视网膜下液、视网膜内层紊乱和椭圆体带破裂。比较临床结果,主要 BRVO 在最初 12 个月内需要更多的玻璃体内抗 VEGF 注射,并且视力预后更差。与黄斑 BRVO 相比,主要 BRVO 中有更高比例的患者在 6 个月后需要额外的治疗。对抗 VEGF 反应不佳的患者在基线时有更高的房水 VEGF 水平和中央视网膜厚度(CST)。总之,主要 BRVO 患者需要更多和更长时间的治疗,并且视力预后更差。对抗 VEGF 反应不佳的 BRVO 在基线时 CST 更大,房水 VEGF 水平更高。